National Medical Products Administration: Uniformly revise the instructions for the injection formulation of Rennetidine Hydrochloride.

The National Medical Products Administration recently issued an announcement. Based on the evaluation results of adverse drug reactions, in order to further protect the safety of public drug use, the National Medical Products Administration has decided to uniformly revise the instructions for the injection formulation of ranitidine hydrochloride. All holders of the marketing authorization for the above-mentioned drugs shall revise the instructions in accordance with relevant regulations such as the "Drug Registration Management Measures" and the requirements of the annex, and submit them to the provincial drug supervision and administration department for record before August 12, 2025. Marketing authorization holders of drugs should conduct in-depth research on the mechanisms of new adverse reactions, take effective measures to promote and train on drug use and safety issues, and guide doctors and pharmacists to use drugs rationally.